Centrum 7/6  banner

Aurobindo receives FDA approval for deflazacort tablets

Print Friendly, PDF & Email

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application deflazacort tablets, 6mg, 18mg, 30mg, & 36mg. Aurobindo Pharma’s deflazacort tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), EMFLAZA Tablets manufactured by PTC Therapeutics Inc.

Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.


ECRM_06-01-22


Comments are closed.

PP_1170x120_10-25-21